The androgenic anabolic steroid tetrahydrogestrinone produces dioxin-like effects via the aryl hydrocarbon receptor

Toxicology in Vitro

Volumn 26, Issue 7, 2012, Pages 1129-1133

  Moon, Hyo Youl ^a,b   Kim, Sun Hee ^c   Ryu, Sung Ho ^a   Suh, Pann Ghill ^b  

^a Pohang University of Science and Technology (POSTECH)   (South Korea)

^b Ulsan National Institute of Science and Technology   (South Korea)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Aryl hydrocarbon receptor; Dioxin; Tetrahydrogestrinone

Indexed keywords

ACTIVATING PROTEIN 1; ANABOLIC AGENT; AROMATIC HYDROCARBON RECEPTOR; CH 223191; CYTOCHROME P450 1A1; DIOXIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; MESSENGER RNA; ONCOPROTEIN; PROTEIN INHIBITOR; PROTEIN P53; TETRAHYDROGESTRINONE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANDROGEN RESPONSIVE ELEMENT; ARTICLE; CARCINOGENESIS; CARCINOGENIC ACTIVITY; DIOXIN RESPONSIVE ELEMENT; DNA STRUCTURE; ENDOCRINE SYSTEM; ENZYME ACTIVATION; ENZYME ACTIVITY; ESTROGEN RESPONSIVE ELEMENT; GENE TARGETING; GLUCOCORTICOID RESPONSIVE ELEMENT; HORMONE RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; ONCOGENE C MYC; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; REPORTER GENE; XENOBIOTIC METABOLISM;

AZO COMPOUNDS; CYTOCHROME P-450 CYP1A1; DIOXINS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENES, REPORTER; GESTRINONE; HEP G2 CELLS; HEPATOCYTES; HUMANS; LUCIFERASES; PYRAZOLES; RECEPTORS, ARYL HYDROCARBON; RESPONSE ELEMENTS; RNA, MESSENGER;

EID: 84866050829     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2012.05.009     Document Type: Article

References (36)

1. Bahrke M.S., Yesalis C.E. Abuse of anabolic androgenic steroids and related substances in sport and exercise. Curr. Opin. Pharmacol. 2004, 4:614-620.
2. Burczynski M.E., Penning T.M. Genotoxic polycyclic aromatic hydrocarbon ortho-quinones generated by aldo-keto reductases induce CYP1A1 via nuclear translocation of the aryl hydrocarbon receptor. Cancer Res. 2000, 60:908-915.
3. Calfee R., Fadale P. Popular ergogenic drugs and supplements in young athletes. Pediatrics 2006, 117:e577-589.
4. Castagnaro M., Yandell D.W., Dockhorn-Dworniczak B., Wolfe H.J., Poremba C. Androgen receptor gene mutations and p53 gene analysis in advanced prostate cancer. Verh. Dtsch. Ges. Pathol. 1993, 77:119-123.
5. Catlin D.H., Sekera M.H., Ahrens B.D., Starcevic B., Chang Y.C., Hatton C.K. Tetrahydrogestrinone: discovery, synthesis, and detection in urine. Rapid Commun. Mass Spectrom. 2004, 18. 1245-1049.
6. Chaturvedi N.K., Kumar S., Negi S., Tyagi R.K. Endocrine disruptors provoke differential modulatory responses on androgen receptor and pregnane and xenobiotic receptor: potential implications in metabolic disorders. Mol. Cell. Biochem. 2010, 345:291-308.
7. Ciolino H.P., Daschner P.J., Yeh G.C. Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. Cancer Res. 1998, 58:5707-5712.
8. Cole P., Trichopoulos D., Pastides H., Starr T., Mandel J.S. Dioxin and cancer: a critical review. Regul. Toxicol. Pharmacol. 2003, 38:378-388.
9. Dolcet X., Llobet D., Pallares J., Matias-Guiu X. NF-kB in development and progression of human cancer. Virchows Arch. 2005, 446:475-482.
10. Edis A.J., Levitt M. Anabolic steroids and colonic cancer. Med. J. Aust. 1985, 142:426-427.
11. Feinberg M.J., Lumia A.R., McGinnis M.Y. The effect of anabolic-androgenic steroids on sexual behavior and reproductive tissues in male rats. Physiol. Behav. 1997, 62:23-30.
12. Flick M.B., Sapi E., Kacinski B.M. Hormonal regulation of the c-fms proto-oncogene in breast cancer cells is mediated by a composite glucocorticoid response element. J. Cell. Biochem. 2002, 85:10-23.
13. Frey H. Liver cancer following use of anabolic steroids?. Tidsskr. Nor. Laegeforen. 1973, 93:2499-2500.
14. Hankinson O. The aryl hydrocarbon receptor complex. Annu. Rev. Pharmacol. Toxicol. 1995, 35:307-340.
15. Hawinkels L.J., Zuidwijk K., Verspaget H.W., de Jonge-Muller E.S., van Duijn W., Ferreira V., Fontijn R.D., David G., Hommes D.W., Lamers C.B., Sier C.F. VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis. Eur. J. Cancer 2008, 44:1904-1913.
16. Hurst C.H., Abbott B., Schmid J.E., Birnbaum L.S. 2(3), pp. 7,8-tetrachlorodibenzo-p-dioxin (TCDD) disrupts early morphogenetic events that form the lower reproductive tract in female rat fetuses. Toxicol. Sci. 2002, 65:87-98.
17. Jana N.R., Sarkar S., Ishizuka M., Yonemoto J., Tohyama C., Sone H. Cross-talk between 2,3,7,8-tetrachlorodibenzo-p-dioxin and testosterone signal transduction pathways in LNCaP prostate cancer cells. Biochem. Biophys. Res. Commun. 1999, 256:462-468.
18. Jesser C., Mucci L., Farmer D., Moon C., Li H., Gaziano J.M., Stampfer M., Ma J., Kantoff P. Effects of G/A polymorphism, rs266882, in the androgen response element 1 of the PSA gene on prostate cancer risk, survival and circulating PSA levels. Br. J. Cancer 2008, 99:1743-1747.
19. Johnson F.L., Lerner K.G., Siegel M., Feagler J.R., Majerus P.W., Hartmann J.R., Thomas E.D. Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma. Lancet 1972, 2:1273-1276.
20. Kim S.H., Henry E.C., Kim D.K., Kim Y.H., Shin K.J., Han M.S., Lee T.G., Kang J.K., Gasiewicz T.A., Ryu S.H., Suh P.G. Novel compound 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide (CH-223191) prevents 2,3,7,8-TCDD-induced toxicity by antagonizing the aryl hydrocarbon receptor. Mol. Pharmacol. 2006, 69:1871-1878.
21. Lasne F., Martin L., de Ceaurriz J., Larcher T., Moullier P., Chenuaud P. "Genetic Doping" with erythropoietin cDNA in primate muscle is detectable. Mol. Ther. 2004, 10:409-410.
22. Li J., Wang E., Rinaldo F., Datta K. Upregulation of VEGF-C by androgen depletion: the involvement of IGF-IR-FOXO pathway. Oncogene 2005, 24:5510-5520.
23. Nesslinger N.J., Shi X.B., deVere White R.W. Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53. Cancer Res. 2003, 63:2228-2233.
24. Pelengaris S., Khan M., Evan G.I. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 2002, 109:321-334.
25. Petroff B.K., Gao X., Ohshima K., Shi F., Son D.S., Roby K.F., Rozman K.K., Watanabe G., Taya K., Terranova P.F. Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on serum inhibin concentrations and inhibin immunostaining during follicular development in female Sprague-Dawley rats. Reprod. Toxicol. 2002, 16:97-105.
26. Salvador J.P., Sanchez-Baeza F., Marco M.P. Preparation of antibodies for the designer steroid tetrahydrogestrinone and development of an enzyme-linked immunosorbent assay for human urine analysis. Anal. Chem. 2007, 79:3734-3740.
27. Shahidi N.T. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin. Ther. 2001, 23:1355-1390.
28. Shimada K., Nakamura M., Ishida E., Kishi M., Konishi N. Androgen and the blocking of radiation-induced sensitization to Fas-mediated apoptosis through c-jun induction in prostate cancer cells. Int. J. Radiat. Biol. 2003, 79:451-462.
29. Takahashi A., Kohri K., Ohnuki T., Hebisawa A., Nagai A. Relationship between p 53 gene mutation and MDR 1 gene expression in surgically resected non-small cell lung cancer. Nihon Kokyuki Gakkai Zasshi 1999, 37:964-969.
30. Tentori L., Graziani G. Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk?. Pharmacol. Res. 2007, 55:359-369.
31. Teraoka H., Dong W., Tsujimoto Y., Iwasa H., Endoh D., Ueno N., Stegeman J.J., Peterson R.E., Hiraga T. Induction of cytochrome P450 1A is required for circulation failure and edema by 2,3,7,8-tetrachlorodibenzo-p-dioxin in zebrafish. Biochem. Biophys. Res. Commun. 2003, 304:223-228.
32. Thiblin I., Petersson A. Pharmacoepidemiology of anabolic androgenic steroids: a review. Fundam. Clin. Pharmacol. 2005, 19:27-44.
33. Toyoshiba H., Walker N.J., Bailer A.J., Portier C.J. Evaluation of toxic equivalency factors for induction of cytochromes P450 CYP1A1 and CYP1A2 enzyme activity by dioxin-like compounds. Toxicol. Appl. Pharmacol. 2004, 194:156-168.
34. Whitlock J.P. Induction of cytochrome P4501A1. Annu. Rev. Pharmacol. Toxicol. 1999, 39:103-125.
35. Wilson J.D. Androgen abuse by athletes. Endocr. Rev. 1988, 9:181-199.
36. Yu J.C., Hsiung C.N., Hsu H.M., Bao B.Y., Chen S.T., Hsu G.C., Chou W.C., Hu L.Y., Ding S.L., Cheng C.W., Wu P.E., Shen C.Y. Genetic variation in the genome-wide predicted estrogen response element-related sequences is associated with breast cancer development. Breast Cancer Res. 2011, 13:R13.